Zanolimumab
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] Development of the drug was ultimately discontinued with termination of all trials.[5]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Molar mass | 147 kg/mol |
  (what is this?) (verify) | |
References
- Genmab initiates Phase II Study with HuMax-CD4 Archived May 16, 2008, at the Wayback Machine
- "Archived copy". Archived from the original on April 11, 2010. Retrieved August 20, 2010.CS1 maint: archived copy as title (link)
- Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
- "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.